Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots.
Worrying balance sheet with weak fundamentals.
- Bionovate Technologies has significant price volatility in the past 3 months.
- Bionovate Technologies is not covered by any analysts.
Share Price & News
How has Bionovate Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
BIIO underperformed the Medical Equipment industry which returned 9.9% over the past year.
BIIO underperformed the Market in United States of America which returned 1.6% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is Bionovate Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Bionovate Technologies undervalued based on future cash flows and its price relative to the stock market?
Intrinsic Value Based on Future Cash Flows
Bionovate Technologies's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
Bionovate Technologies's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Price Based on Earnings
Bionovate Technologies is loss making, we can't compare its value to the US Medical Equipment industry average.
Bionovate Technologies is loss making, we can't compare the value of its earnings to the United States of America market.
Price Based on Expected Growth
Unable to calculate PEG ratio for Bionovate Technologies, we can't assess if its growth is good value.
Price Based on Value of Assets
Bionovate Technologies has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.
How is Bionovate Technologies expected to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bionovate Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Take a look at our analysis of BIIO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
- While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Bionovate Technologies's filings and announcements here.
- Explore growth companies in the Healthcare industry.
How has Bionovate Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Bionovate Technologies does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Bionovate Technologies's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Bionovate Technologies's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.
Return on Equity
It is difficult to establish if Bionovate Technologies has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
Return on Assets
Unable to establish if Bionovate Technologies has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as past financial data has not been reported.
Return on Capital Employed
It is difficult to establish if Bionovate Technologies improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
How is Bionovate Technologies's financial position?
Financial Position Analysis
Unable to compare short term assets to short term liabilities as Bionovate Technologies has not reported sufficient balance sheet data.
Bionovate Technologies has no long term commitments.
Debt to Equity History and Analysis
Bionovate Technologies has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
Irrelevant to check if Bionovate Technologies's debt level has increased considering it has negative shareholder equity.
Unable to establish if Bionovate Technologies has a high level of physical assets or inventory without balance sheet data.
Bionovate Technologies has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Information is not available.
Unable to confirm if Bionovate Technologies has at least 1 year of cash runway based on growing free cash flows without relevant data.
What is Bionovate Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield and Payments Analysis
Unable to evaluate Bionovate Technologies's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Bionovate Technologies's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Bionovate Technologies has not reported any payouts.
Unable to verify if Bionovate Technologies's dividend has been increasing as the company has not reported any payouts.
Current Payout to Shareholders
Unable to calculate sustainability of dividends as Bionovate Technologies has not reported any payouts.
Future Payout to Shareholders
Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
What is the CEO of Bionovate Technologies's salary, the management and board of directors tenure and is there insider trading?
Cohen Mizrahi (55yo)
Dr. Cohen Mizrahi serves as President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director of Bionovate Technologies Corp since April 23, 2019. Dr. Mizrahi has been working ...
No 3 month open market individual insider trading information.
Cohen Mizrahi (55yo)
- Tenure: 0.4yrs
Cohen Mizrahi (55yo)
- Tenure: 0.4yrs
Bionovate Technologies Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Bionovate Technologies Corp.
- Ticker: BIIO
- Exchange: OTCPK
- Founded: 2010
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$778.987k
- Shares outstanding: 15.58m
- Website: https://null
- Bionovate Technologies Corp.
- Rothschild Boulevard 22
- Tel Aviv
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BIIO||OTCPK (Pink Sheets LLC)||Yes||Common Shares||US||USD||Apr 2014|
Bionovate Technologies Corp., a medical device company, focuses on developing automated treatment for age spots. It intends to develop and provide automated computerized systems that treat age spots anywhe ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/09/20 01:09|
|End of Day Share Price||2019/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.